Bruker Corporation (NASDAQ:BRKR) Receives Consensus Recommendation of “Hold” from Analysts

Bruker Corporation (NASDAQ:BRKR) has received an average rating of “Hold” from the fifteen ratings firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, six have given a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $50.5385.

BRKR has been the subject of a number of analyst reports. Guggenheim lowered their target price on shares of Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Citigroup boosted their target price on shares of Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. Jefferies Financial Group set a $50.00 target price on shares of Bruker in a research note on Thursday, February 12th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, UBS Group boosted their target price on shares of Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th.

Insiders Place Their Bets

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bruker

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its position in Bruker by 5,291.2% in the first quarter. NewEdge Advisors LLC now owns 1,833 shares of the medical research company’s stock valued at $66,000 after acquiring an additional 1,799 shares during the last quarter. Essential Partners LLC purchased a new stake in Bruker in the first quarter valued at $36,000. Groupe la Francaise purchased a new stake in Bruker in the first quarter valued at $1,222,000. Liontrust Investment Partners LLP lifted its position in Bruker by 113.3% in the first quarter. Liontrust Investment Partners LLP now owns 3,844 shares of the medical research company’s stock valued at $139,000 after acquiring an additional 2,042 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Bruker by 2.1% in the 1st quarter. Janus Henderson Group PLC now owns 100,380 shares of the medical research company’s stock valued at $3,625,000 after purchasing an additional 2,090 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Stock Performance

Shares of BRKR stock opened at $56.39 on Friday. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. The firm has a fifty day moving average price of $42.57 and a 200 day moving average price of $43.45. The company has a market cap of $8.58 billion, a P/E ratio of -234.96, a PEG ratio of 1.92 and a beta of 1.31. Bruker has a 12 month low of $28.53 and a 12 month high of $64.54.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts predict that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.